First test of Donor-Derived 'Living Drug' for Tough-to-Treat lymphomas
NCT ID NCT03939026
Summary
This early-phase study tested the safety of a new type of cancer treatment called ALLO-501 in adults with lymphoma that has returned or not responded to standard chemotherapy. The treatment involves giving patients immune cells (CAR T-cells) from a healthy donor, not the patient themselves, after a short course of chemotherapy drugs to prepare the body. Researchers monitored 50 participants closely to understand the treatment's safety, how the cells behave in the body, and if it helps fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
St. Davids South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.